However, the advent of various immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors and programmed death ligand-1 (PD-L1) inhibitors, offers a suitable alternative, that has dramatically changed the treatment paradigm of SCLC (Reck et al., 2016). Here, CD274 is linked to small cell lung carcinoma.